Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Mayo Collaborative Services v. Prometheus Laboratories, Inc. | Statement: [Association for Molecular Pathology v. Myriad Genetics, Inc., relatedTo, Mayo Collaborative Services v. Prometheus Laboratories, Inc.]

Target entity: Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Context triple: [Association for Molecular Pathology v. Myriad Genetics, Inc., relatedTo, Mayo Collaborative Services v. Prometheus Laboratories, Inc.]

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. In re Chakrabarty
  In re Chakrabarty is a landmark 1980 U.S. Supreme Court case that held genetically engineered living organisms can be patented, significantly shaping modern biotechnology patent law.
• C. In re Diehr
  In re Diehr is a landmark 1981 U.S. Supreme Court patent law decision that clarified the patent eligibility of computer-implemented inventions under 35 U.S.C. § 101.
• D. Leahy–Smith America Invents Act
  The Leahy–Smith America Invents Act is a 2011 U.S. patent reform law that overhauled the patent system, including shifting to a first-inventor-to-file regime and creating new post-grant review procedures.
• E. Cohen–Boyer recombinant DNA patents
  The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Triple: [Association for Molecular Pathology v. Myriad Genetics, Inc., relatedTo, Mayo Collaborative Services v. Prometheus Laboratories, Inc.]

Mayo Collaborative Services v. Prometheus Laboratories, Inc. is a landmark 2012 U.S. Supreme Court case that limited the patentability of medical diagnostic methods by holding that laws of nature and their routine applications are not eligible for patent protection.

Target entity: Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Target entity description: Mayo Collaborative Services v. Prometheus Laboratories, Inc. is a landmark 2012 U.S. Supreme Court case that limited the patentability of medical diagnostic methods by holding that laws of nature and their routine applications are not eligible for patent protection.

• A. Association for Molecular Pathology v. Myriad Genetics, Inc.
  Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.
• B. In re Chakrabarty
  In re Chakrabarty is a landmark 1980 U.S. Supreme Court case that held genetically engineered living organisms can be patented, significantly shaping modern biotechnology patent law.
• C. In re Diehr
  In re Diehr is a landmark 1981 U.S. Supreme Court patent law decision that clarified the patent eligibility of computer-implemented inventions under 35 U.S.C. § 101.
• D. Leahy–Smith America Invents Act
  The Leahy–Smith America Invents Act is a 2011 U.S. patent reform law that overhauled the patent system, including shifting to a first-inventor-to-file regime and creating new post-grant review procedures.
• E. Cohen–Boyer recombinant DNA patents
  The Cohen–Boyer recombinant DNA patents were foundational biotechnology patents that covered key methods for creating recombinant DNA, enabling modern genetic engineering and the biotechnology industry.
• F. None of above. chosen